{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu Y"],"funding":["Beijing Municipal Health Commission","National Natural Science Foundation of China","Capital Funds for Health Improvement and Research"],"pagination":["e70124"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11570871"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(11)"],"pubmed_abstract":["<h4>Aims</h4>Patients with glioblastoma multiforme (GBM) do not benefit from current cancer treatments, and their prognosis is dismal. This study aimed to investigate the potential synergistic effects of TS-2021, a third-generation oncolytic adenovirus, combined with the PARP inhibitor olaparib in GBM.<h4>Methods</h4>TS-2021's impact on p66shc-induced apoptosis, DNA damage response, and poly (ADP-ribose) polymerase (PARP) activation was evaluated in GBM cells. The synergistic effect of TS-2021 and olaparib was examined in GBM cell lines and an immunocompetent mouse model of GBM. Mechanistic studies focused on the role of p66shc phosphorylation in the observed effects.<h4>Results</h4>TS-2021 triggered p66shc-induced apoptosis, DNA damage response, and PARP activation. The combination of TS-"],"journal":["CNS neuroscience & therapeutics"],"pubmed_title":["Olaparib Enhances the Efficacy of Third-Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc-Induced Apoptosis."],"pmcid":["PMC11570871"],"funding_grant_id":["11000023T000002044300-3","11000023T000002044300‐3","CFH,2024-1-1071","52373129"],"pubmed_authors":["Liu Y","Wang P","Zhang J","Fang S","Liu F"],"additional_accession":[]},"is_claimable":false,"name":"Olaparib Enhances the Efficacy of Third-Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc-Induced Apoptosis.","description":"<h4>Aims</h4>Patients with glioblastoma multiforme (GBM) do not benefit from current cancer treatments, and their prognosis is dismal. This study aimed to investigate the potential synergistic effects of TS-2021, a third-generation oncolytic adenovirus, combined with the PARP inhibitor olaparib in GBM.<h4>Methods</h4>TS-2021's impact on p66shc-induced apoptosis, DNA damage response, and poly (ADP-ribose) polymerase (PARP) activation was evaluated in GBM cells. The synergistic effect of TS-2021 and olaparib was examined in GBM cell lines and an immunocompetent mouse model of GBM. Mechanistic studies focused on the role of p66shc phosphorylation in the observed effects.<h4>Results</h4>TS-2021 triggered p66shc-induced apoptosis, DNA damage response, and PARP activation. The combination of TS-","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-07-16T23:50:07.475Z","creation":"2025-04-07T10:10:06.338Z"},"accession":"S-EPMC11570871","cross_references":{"pubmed":["39552450"],"doi":["10.1111/cns.70124"]}}